NCT05327088View on ClinicalTrials.gov

Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 12, 2021

Primary Completion Date

February 12, 2022

Study Completion Date

March 12, 2022

Conditions
Epidural AnesthesiaLabor Pain
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.

DRUG

Nalbuphine

Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine

Trial Locations (1)

Unknown

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05327088 - Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia | Biotech Hunter | Biotech Hunter